Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 20/20 | 0.71 |
| ▸ | PDE4A | P27815 | 7/20 | 0.71 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.71 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116464 | 1.00 | PDE4D (0.71) | PDE4DPDE4APDE4BPDE4CSLC6A2 | |
| SCHEMBL4116470 | 1.00 | PDE4D (0.71) | PDE4DPDE4APDE4BPDE4CSLC6A2 | |
| SCHEMBL4118467 | 0.87 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4CSLC6A2 | |
| SCHEMBL4118463 | 0.87 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4CSLC6A2 | |
| SCHEMBL4118460 | 0.87 | PDE4D (0.80) | PDE4DPDE4APDE4BPDE4CSLC6A2 | |
| SCHEMBL7146869 | 0.85 | PDE4D (0.79) | PDE4DPDE4APDE4BPDE4CSLC6A2 | |
| SCHEMBL7146867 | 0.85 | PDE4D (0.79) | PDE4DPDE4APDE4BPDE4CSLC6A2 | |
| SCHEMBL4128491 | 0.85 | PDE4D (0.81) | PDE4DPDE4APDE4BPDE4CSLC6A2 | |
| SCHEMBL4128505 | 0.85 | PDE4D (0.81) | PDE4DPDE4APDE4BPDE4CSLC6A2 | |
| SCHEMBL7146863 | 0.85 | PDE4D (0.79) | PDE4DPDE4APDE4BPDE4CSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042879-A1 | PHTHALAZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON SHINYAKU CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1873147-A1 | PHTHALAZINONE DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME | Nippon Shinyaku Co., Ltd. (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042879-A1 | PHTHALAZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IL4, PDE4A, PDE12 | PDE4D 13/4885PDE4A 2/4885PDE4B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.